|
Palo Alto, CA, December 3, 2007 — Telik, Inc. (Nasdaq:
TELK) announced it will report data from the Phase 1 dose-escalation study of TELINTRA® (ezatiostat HCl) Tablets at the 49 th annual meeting of the American Society of Hematology. The presentation is scheduled for Saturday, December 8, 2007, from 5:30 to 7:30 pm in Hall B3 and B4 at the Georgia World Congress Center in Atlanta. The presentation (Abstract # 1454, Board # 608) is titled: “Phase 1 Dose Escalation Study of TLK199 Tablets (TELINTRA), a Novel Glutathione Analog, in Myelodysplastic Syndrome.” It will be presented during the poster session “Myelodysplastic Syndromes: Clinical Studies, Including Transplantation.”
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced drug development candidates are TELCYTA®, a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small cell lung cancer; and TELINTRA®, which is in development for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP™, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com
TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2007 Press Releases2006
Press Releases
2005
Press ReleasesEvents |
TELIK ANNOUNCES TELINTRA PRESENTATION AT AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING
